FDA on RECORD Readjudication: Avandia Does Not Up CV RiskFDA on RECORD Readjudication: Avandia Does Not Up CV Risk

The first day of a 2-day meeting on rosiglitazone included presentations from FDA, GlaxoSmithKline, Duke University reviewers, and 1 dissenting FDA official. Today the panel will vote on the drug's future. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news